ELVN FY 2024 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$105M

Net Income

-$89M

EPS (Diluted)

$-1.89

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$73M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$326M

Total Liabilities

$16M

Stockholders' Equity

$310M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$105M	-$84M	-25.2%
Net Income	-$89M	-$72M	-24.4%